Alcides Euzebio Tavares Xavier

Alcides Euzebio Tavares Xavier

Auto-generated profile, based on publicly available information

Alcides Euzebio Tavares Xavier

¹Department of Genetics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2024 in Molecular and Cellular Endocrinology
Verified
Journal Article
Closed access
LVLuciana Chain Veronez
Luciana Chain Veronez
AXAlcides Euzebio Tavares Xavier
Alcides Euzebio Tavares Xavier
LNLuiz Fernando Nagano
Luiz Fernando Nagano
CCCarolina Alves Pereira Correa
Carolina Alves Pereira Correa
KBKleiton Silva Borges
Kleiton Silva Borges
CSCarlos Alberto Scrideli
Carlos Alberto Scrideli

9 July 2026 in The Cerebellum
Verified
Journal Article
Open access
PDF file
JSJonas José da Silva
Jonas José da Silva
MFManuela Eduarda de França
Manuela Eduarda de França
AXAlcides Euzebio Tavares Xavier
Alcides Euzebio Tavares Xavier
MBMariane Minussi Baptistella
Mariane Minussi Baptistella
EPEduardo Afonso da Silva Pereira
Eduardo Afonso da Silva Pereira
CSCarlos Alberto Scrideli
Carlos Alberto Scrideli
Medulloblastoma (MB), the most common malignant pediatric brain tumor, is classified into four molecular groups: WNT, SHH, G3, and G4. G3 and G4 MBs are characterized by poor prognosis and high metastatic potential. Although USP2 (ubiquitin-specific peptidase 2) has been described as a prognostic biomarker and a promising therapeutic target in several cancer types, its role in the pathogenesis of G3 and G4 MBs remains unexplored. In this study, USP2 expression was investigated through in silico analyses, public datasets (GSE85217), and tumor samples from 54 pediatric MB patients. In addition, the effects of USP2 inhibition were evaluated in two G3/G4 MB cell lines (D283 Med and USP-13) using ML364, a selective USP2 inhibitor. USP2 was overexpressed in G3 and G4 MBs and was associated with metastasis and unfavorable clinical outcomes. Furthermore, ML364 treatment reduced USP2 protein expression level, as well as cell viability, migration, invasion, and colony-forming capacity in both cell lines. These findings indicate that USP2 is upregulated in pediatric G3 and G4 MBs and support its potential role as a biomarker of poor prognosis and a therapeutic target in these molecular subgroups.